-+ 0.00%
-+ 0.00%
-+ 0.00%
Novo Nordisk (NVO) Could Be 46% Undervalued After Wegovy Pill Prescription Focus
Share
Listen to the news

Novo Nordisk (NYSE:NVO) drew fresh attention after analysts highlighted more than eight million cumulative prescriptions for its oral Wegovy pill and the approaching earnings report, prompting investors to reassess the stock’s recent pullback.

Over the past month, Novo Nordisk’s 1 month share price return of 9.21% has rebuilt some confidence after a 90 day share price decline of 9.28% and a year to date share price fall of 20.54%. The 1 year total shareholder return is down 10.8%, which points to improving short term momentum against a weaker multi year experience as investors weigh Wegovy pill demand against past volatility and recent valuation resets.

Scan how Novo Nordisk’s rerating compares with other pharmaceutical and biotech stocks by reviewing our curated list of 32 high quality undervalued stocks positioned for a potential recovery in sentiment.

Novo Nordisk has bounced hard off the lows, yet the long term chart still reflects a heavy reset. Does the current valuation still leave enough upside to justify the Wegovy pill and obesity story risk?

Most Popular Narrative: 45.7% Undervalued

Set against Novo Nordisk’s last close at $41.63, the most followed narrative pegs fair value at $76.63, which frames the recent pullback as a potential disconnect between market price and the obesity franchise story.

According to ricksilva20, an investor in the Simply Wall St Community who built the narrative, the reset in Novo Nordisk’s valuation reflects a pricing squeeze in the US rather than a collapse in business quality or long term demand for its treatments.

A Novo Nordisk é uma máquina de qualidade excecional (ROA de 23%, quase sem goodwill, 11% de crescimento composto durante uma década) a atravessar uma compressão de preços nos EUA que o mercado está a tratar como permanente , paga hoje 11x lucros, contra mais de 40x em 2021. tenho a ideia de que o número de doentes tratados no Ocidente multiplica por cinco ou seis até 2033, à medida que a Europa, o Canadá e a Austrália criam regimes de comparticipação , Portugal, com 2 milhões de adultos obesos e o decreto do Infarmed em preparação, é um exemplo entre muitos.

See why 2 investors see Novo Nordisk as 46% undervalued.

The narrative uses a 6% discount rate and assumes Novo Nordisk can continue to convert its obesity and diabetes pipeline into solid profitability, pointing to a fair value of $76.63 per share. That compares to today’s share price near the low $40s, which leaves a wide gap for investors to judge against their own expectations for Wegovy pill uptake, pricing pressure and future product cycles.

Under this view, the key swing factors are not just prescription counts but whether new therapies such as CagriSema can refresh the franchise before existing patents fade, and whether profit per patient finds a stable level. Readers weighing Novo Nordisk’s recent US rerating against this long term thesis can use the narrative’s fair value as one reference point rather than a forecast or target.

Result: Fair Value of $76.63 (UNDERVALUED)

Still, two pressure points could challenge that thesis: a deeper or prolonged US pricing squeeze, and weaker than expected uptake for newer therapies such as CagriSema.

Find out about the key risks to this Novo Nordisk narrative.

Next Steps

Mixed messages in the Novo Nordisk story today. If you want to move quickly from headline noise to your own judgment, start with the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Novo Nordisk?

If Novo Nordisk sharpened your focus on pricing power, growth risk and valuation resets, do not stop here. Broaden your watchlist now with targeted screeners built to surface clear, data driven ideas.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending